Ncardia is a stem cell drug discovery & development company operating worldwide with facilities and offices in Belgium, the Netherlands, Germany and the USA. The company has been established from the merger of Pluriomics and Axiogenesis. Ncardia is built on the belief and trust that stem technology will help to get better medicines to patients faster. The goal of the company is to be the supportive and trusted partner for scientists operating in the hiPSC drug discovery and development space including cardiovascular and neural safety and efficacy studies.